Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study-Reference-Cited by-同舟云学术

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Published:2021-07 Issue:7 Volume:22 Page:959-969
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gainor Justin F,Curigliano Giuseppe,Kim Dong-Wan,Lee Dae Ho,Besse Benjamin,Baik Christina S,Doebele Robert C,Cassier Philippe A,Lopes Gilberto,Tan Daniel S W,Garralda Elena,Paz-Ares Luis G,Cho Byoung Chul,Gadgeel Shirish M,Thomas Michael,Liu Stephen V,Taylor Matthew H,Mansfield Aaron S,Zhu Viola W,Clifford Corinne,Zhang Hui,Palmer Michael,Green Jennifer,Turner Christopher D,Subbiah Vivek

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. State-of-the-art strategies for targeting RET-dependent cancers;Subbiah;J Clin Oncol,2020

2. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial;Drilon;Lancet Oncol,2016

3. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial;Yoh;Lancet Respir Med,2017

4. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma;Hida;Lung Cancer,2019

5. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial;Lee;Ann Oncol,2017

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer;Cancer Letters;2024-11

2. Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study;Lung Cancer;2024-10

3. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

4. Precision oncology: current and future platforms for treatment selection;Trends in Cancer;2024-09

5. Tips for Accelerating BOIN Design;Therapeutic Innovation & Regulatory Science;2024-08-23